STEROID-INDUCED GLAUCOMAS
GUEST AUTHOR
YUSRA TANVEER
Ajmal Khan Tibbiya College
Aligarh Muslim University
Aligarh Muslim University
INTRODUCTION:
Corticosteroids are a double-edged sword.
While they are useful in the management of various conditions, they also have
multiple ocular and systemic side effects which may even be life threatening at
times.
In certain countries steroids are easily
available over-the-counter while online pharmacies are also responsible for the
unmonitored accessibility of these agents.
Ocular side effects include: increased
susceptibility or reactivation of certain infections, cataract and increase in intra-ocular pressure (IOP).
Prolonged elevation of IOP can cause damage to
the optic nerve leading to the development of steroid-induced glaucoma (SIG).
PATHOGENESIS:
SIG is a form of open angle glaucoma.
The exact mechanism responsible for elevated
IOP after steroid intake is not clear.
It is most likely associated with reduced
facility of aqueous outflow.
Other theories include:
Stabilization of lysosomal membranes and
accumulation of polymerized glycosaminoglycans (GAGs) in the trabecular meshwork (TM).
Hydration of GAGs leads to biological edema in the TM and consequently reduced
aqueous outflow. Corticosteroids, which stabilize lysosomal membranes, could
reduce the release of lysosomal hyaluronidase resulting in a relative
inhibition of hyaluronate depolymerization.
Ultra-structurally, accumulation of basement
membrane like material staining for type IV collagen is also seen in SIG.
Extracellular deposition of extracellular matrix material in the TM shows 2
patterns: Fingerprint-like deposition of material in the uveal meshwork and
accumulation of fine fibrillar material in the juxtacanalicular region.
Corticosteroids cause inhibition of phagocytic
properties of endothelial cells lining the TM leading to
accumulation of aqueous debris.
Glucocorticoids decrease synthesis of
prostaglandins, which regulate aqueous outflow. They also inhibit TM cell
arachidonic acid metabolism and reduce phagocytic activity of TM cells.
Dexamethasone also causes cross-linked actin network formation. However, the effect of such an alteration of cellular cytoskeleton on TM cell
function is not clear.
There is some genetic influence in the
development of SIG, as several genes have been found to be associated with
protective as well as damaging glucocorticoid treated TM cells. A number of genes are
suspected though not yet proven to have a role in the development of SIG. These
include: MYOC (previously called trabecular meshwork induced glucocorticoid
response [TIGR]) gene and genes regulating alpha1 chymotrypsin, pigment
epithelium derived factor, cornea-derived transcript 6, prostaglandin D2
synthetase, growth arrest specific 1, decorin, insulin like growth factor
binding protein 2, ferritin light chain, fibulin-1C and others.
EPIDEMIOLOGY:
Steroid induced IOP elevation can occur at any
age.
Children may have a severe ocular hypertensive
response to topical steroids.
In a study SIG was responsible for 1/4th of
all cases of acquired glaucoma in children.
According to Becker and also Armaly, individuals
can be categorized into high, intermediate and low responders to topical
steroids.
HIGH RESPONDERS: Had IOP increase above 31 mmHg or 15 mmHg above baseline.
INTERMEDIATE RESPONDERS: Had IOP increase between 20-31 mmHg or between 6-15 mmHg above baseline.
LOW (NON) RESPONDERS: Had IOP less than 20 mmHg or rise of less than 6 mmHg from baseline.
HIGH RESPONDERS: Had IOP increase above 31 mmHg or 15 mmHg above baseline.
INTERMEDIATE RESPONDERS: Had IOP increase between 20-31 mmHg or between 6-15 mmHg above baseline.
LOW (NON) RESPONDERS: Had IOP less than 20 mmHg or rise of less than 6 mmHg from baseline.
RISK FACTORS:
Factors which increase the risk of SIG
include=
1. Patient related factors: Glaucoma or
glaucoma suspects have marked rise in IOP levels after several weeks of topical
corticosteroid therapy. First degree relatives of POAG patients have higher
risk of being steroid responders.
2. High myopia, patients with H/O penetrating
keratoplasty or refractive surgeries may have a high IOP response which gets
masked due to low central corneal thickness, Ocular rigidity changes, Corneal
edema and fluid accumulation beneath the LASIK flap.
3. Extremes of age: Children below 10 years of
age and elderly individuals show higher steroid responsiveness.
4. Type I Diabetes mellitus and connective
tissue disease (specially rheumatoid arthritis).
5. Pigment dispersion syndrome and traumatic
angle recession.
6. Systemic disorders such as adrenal adenoma.
ROUTES OF ADMINISTRATION:
Topical: IOP elevation is more common by this
route compared to systemic administration.
Periocular therapy: Long-acting repository
steroids are most liable to cause rise in IOP. A patient’s previous response to
topical steroids does not predict their response to periocular steroids.
Intravitreal injections: Injections of
triamcinolone or depot steroids such as ozurdex can cause elevation of IOP
within 2-4 weeks of the procedure.
Systemic therapy: Injections, tablets (oral),
Skin preparations, Inhalational agents and other systemic steroid use is less
commonly associated with rise in IOP. Use of steroids for muscle building is
another danger for SIG.
The potency and strength of the steroid used
are related to the IOP response which occurs. Often the response does not
correlate to the dosage or duration of treatment.
DURATION OF STEROID ADMINISTRATION:
Raised IOP in susceptible individuals usually
occurs in a few weeks after commencement (average: 4 weeks). However, it may
occur within hours or several years later.
CLINICAL FEATURES:
Signs and symptoms vary with the age of the
patients. Infants present with features of congenital glaucoma such as watering
and photophobia. Adults show features of open angle glaucoma. SIG may be
accompanied with other complications such as mydriasis and ptosis.
DIFFERENTIAL DIAGNOSIS:
Primary open angle glaucoma
Normal tension glaucoma
Juvenile open angle glaucoma
Uveitic glaucoma
Glaucomatocyclitic crisis
MANAGEMENT:
First line of management is discontinuation of
the steroid. Usually IOP returns to normal in a few days or weeks. Patients
require pharmacological IOP lowering during this period.
If steroids cannot be stopped in the patient,
they can be substituted with non adrenal steroids such as: rimexolone,
loteprednol etabonate, fluoromethalone & medrysone.
Depot steroids need to removed by excision and
clearing all steroid deposits in the area.
Intravitreal steroids may require vitrectomy
to remove them.
Steroids can possibly be replaced with
non-steroidal anti-inflammatory agents such as: flurbiprofen, bromfenac,
ketorolac and nepafenac.
If IOP does not respond to medical treatment
then Argon laser trabeculolasty can be tried. It may control IOP until the
steroid-induced hypertensive effect disappears.
Ultimately glaucoma filtering procedures or even glaucoma drainage devices are required in intractable cases.
Ultimately glaucoma filtering procedures or even glaucoma drainage devices are required in intractable cases.
CONCLUSION:
SIG is an avoidable condition which is
aggravated by factors such as easy accessibility, risk factors for IOP
elevation and poor monitoring. Increasing awareness regarding this condition
can lead to a reduction in the prevalence of SIG.